Laura Shawver sold $2.7M of SPRY
director at ARS Pharmaceuticals, Inc.. 200,000 shares at an average of $13.44, traded Dec 2, 2024, filed Dec 4, 2024.
Score components
- +15RoleDirector
- +25Trade size$2.7M at market
- +20Share of holdings soldSold 65% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-028350, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +67,616 | $1.27 | $86k | 277,962 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Common Stock10b5-1 | +29,628 | $1.27 | $38k | 307,590 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -96,343 | $13.55 | $1.3M | 211,247 | Dec 4, 2024 |
| Dec 2, 2024 | SOpen-market sale Common Stock10b5-1 | -901 | $14.34 | $13k | 210,346 | Dec 4, 2024 |
| Dec 3, 2024 | MOption exercise Common Stock10b5-1 | +25,606 | $1.27 | $33k | 235,952 | Dec 4, 2024 |
| Dec 3, 2024 | MOption exercise Common Stock10b5-1 | +62,378 | $3.15 | $196k | 298,330 | Dec 4, 2024 |
| Dec 3, 2024 | SOpen-market sale Common Stock10b5-1 | -87,984 | $13.26 | $1.2M | 210,346 | Dec 4, 2024 |
| Dec 4, 2024 | MOption exercise Common Stock10b5-1 | +14,772 | $3.15 | $47k | 225,118 | Dec 4, 2024 |
| Dec 4, 2024 | SOpen-market sale Common Stock10b5-1 | -14,772 | $13.75 | $203k | 210,346 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -29,628 | $0.00 | $0 | 25,606 | Dec 4, 2024 |
| Dec 2, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -67,616 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 3, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,606 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 3, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -62,378 | $0.00 | $0 | 73,836 | Dec 4, 2024 |
| Dec 4, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,772 | $0.00 | $0 | 59,064 | Dec 4, 2024 |
Related signals
Other insiders at ARS Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $240k 15,000 shares | -66% | |
| 63Notable | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $705k 50,000 shares | -87% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Brent L Saunders director | $1.7M 120,000 shares | -100% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Alexander A Fitzpatrick Chief Legal Officer | $1.5M 102,969 shares | -53% | |
| 5Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $615k 50,002 shares | -19% | |
| 11Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $140k 10,000 shares | -57% | |
| 4Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $560k 50,000 shares | -24% | |
| 5Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $616k 50,000 shares | -19% | |
| 4Weak | ARS Pharmaceuticals, Inc. | Laura Shawver director | $555k 50,000 shares | -19% | |
| 45Moderate | ARS Pharmaceuticals, Inc. | Richard E Lowenthal PRESIDENT AND CEO | $1.2M 100,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.